Literature DB >> 15824109

Tumor suppression by the von Hippel-Lindau protein requires phosphorylation of the acidic domain.

Martijn P Lolkema1, Michelle L Gervais, Cristel M Snijckers, Richard P Hill, Rachel H Giles, Emile E Voest, Michael Ohh.   

Abstract

The tumor suppressor function of the von Hippel-Lindau protein (pVHL) has previously been linked to its role in regulating hypoxia-inducible factor levels. However, VHL gene mutations suggest a hypoxia-inducible factor-independent function for the N-terminal acidic domain in tumor suppression. Here, we report that phosphorylation of the N-terminal acidic domain of pVHL by casein kinase-2 is essential for its tumor suppressor function. This post-translational modification did not affect the levels of hypoxia-inducible factor; however, it did change the binding of pVHL to another known binding partner, fibronectin. Cells expressing phospho-defective mutants caused improper fibronectin matrix deposition and demonstrated retarded tumor formation in mice. We propose that phosphorylation of the acidic domain plays a role in the regulation of proper fibronectin matrix deposition and that this may be relevant for the development of VHL-associated malignancies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15824109     DOI: 10.1074/jbc.M503220200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  VHL inactivation induces HEF1 and Aurora kinase A.

Authors:  Jianyong Xu; Huapeng Li; Bo Wang; Yan Xu; Jiayin Yang; Xiaofei Zhang; Sarah K Harten; Deepa Shukla; Patrick H Maxwell; Duanqing Pei; Miguel A Esteban
Journal:  J Am Soc Nephrol       Date:  2010-09-23       Impact factor: 10.121

2.  Metastatic Renal Cell Cancer-Systemic Therapy.

Authors:  Amit Joshi; Arvind Sahu; Vanita Noronha; Vijay Patil; Kumar Prabhash
Journal:  Indian J Surg Oncol       Date:  2018-01-29

Review 3.  Ubiquitin pathway in VHL cancer syndrome.

Authors:  Michael Ohh
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

4.  RSUME inhibits VHL and regulates its tumor suppressor function.

Authors:  J Gerez; L Tedesco; J J Bonfiglio; M Fuertes; M Barontini; S Silberstein; Y Wu; U Renner; M Páez-Pereda; F Holsboer; G K Stalla; E Arzt
Journal:  Oncogene       Date:  2014-12-15       Impact factor: 9.867

5.  Nek1 phosphorylates Von Hippel-Lindau tumor suppressor to promote its proteasomal degradation and ciliary destabilization.

Authors:  Mallikarjun Patil; Navjotsingh Pabla; Shuang Huang; Zheng Dong
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

6.  Phosphorylation-dependent cleavage regulates von Hippel Lindau proteostasis and function.

Authors:  P German; S Bai; X-D Liu; M Sun; L Zhou; S Kalra; X Zhang; R Minelli; K L Scott; G B Mills; E Jonasch; Z Ding
Journal:  Oncogene       Date:  2016-03-14       Impact factor: 9.867

7.  Elevated cell invasion is induced by hypoxia in a human pituitary adenoma cell line.

Authors:  Daizo Yoshida; Akira Teramoto
Journal:  Cell Adh Migr       Date:  2007-01-27       Impact factor: 3.405

8.  A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy.

Authors:  Sandra Turcotte; Denise A Chan; Patrick D Sutphin; Michael P Hay; William A Denny; Amato J Giaccia
Journal:  Cancer Cell       Date:  2008-07-08       Impact factor: 31.743

9.  The long form of pVHL is artifactually modified by serine protease inhibitor AEBSF.

Authors:  Daniel Tarade; Shelley He; Jonathan St-Germain; Avi Petroff; Anya Murphy; Brian Raught; Michael Ohh
Journal:  Protein Sci       Date:  2020-06-25       Impact factor: 6.725

10.  pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2.

Authors:  Haifeng Yang; Yoji Andrew Minamishima; Qin Yan; Susanne Schlisio; Benjamin L Ebert; Xiaoping Zhang; Liang Zhang; William Y Kim; Aria F Olumi; William G Kaelin
Journal:  Mol Cell       Date:  2007-10-12       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.